• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Microbiome Job Board

Month: April 2022

Finance

Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis

April 28, 2022 Microbiome Times

Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]

Pharma & Human Health

Genetics affects functions of gut microbiome

April 28, 2022 Microbiome Times

New research from Cornell scientists is exploring how human genetics impacts functions of the gut microbiome, and is expanding awareness of the role human genetics plays in shaping the microbiome. The trillions of individual organisms […]

Pharma & Human Health

Protecting the human intestinal microbiome with synthetic biology

April 18, 2022 Microbiome Times

A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Massachusetts Institute of Technology (MIT), using a synthetic biology approach, has developed an engineered live biotherapeutic product (eLBP) that, when […]

Editor's Choice

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

April 15, 2022 Laurence Zitvogel

 

Editor's Choice

Did you miss Probiota Copenhagen 2022? Catch up now!

April 12, 2022 Nina Vinot

With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]

Finance

Microba Life Sciences Completes Successful IPO & Announces Partnership with Ginkgo Bioworks

April 4, 2022 Microbiome Times

Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and […]

Finance

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

April 4, 2022 Microbiome Times

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
    April 15, 2022
  • Did you miss Probiota Copenhagen 2022? Catch up now!
    April 12, 2022
  • A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
    February 18, 2022
  • Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
    February 17, 2022
  • ELIGO v SNIPR: a reflection on IP strategies in a competitive environment
    February 7, 2022
sign up

Sign up to the Microbiome Times newsletter